Summary

The Global Monoclonal Antibodies in Veterinary Health Market is valued approximately at USD 0.82 billion in 2023 and is poised to grow at a rapid compound annual growth rate of 17.10% over the forecast period 2024–2032. With the escalating demand for advanced immunotherapy across the animal health ecosystem, monoclonal antibodies (mAbs) are emerging as a revolutionary class of therapeutics for managing complex and chronic conditions in companion animals. Unlike traditional treatment modalities, mAbs offer highly targeted mechanisms of action with improved safety and reduced side effects, enabling veterinarians to address underlying inflammatory and autoimmune disorders—especially in dermatology and pain management—with surgical precision. As animal owners become increasingly aware of quality-of-life outcomes and long-term wellness, biologics are rapidly gaining favor in veterinary protocols, catalyzing market expansion.
This market’s momentum is being propelled by the convergence of multiple trends: the rising prevalence of allergic dermatitis and osteoarthritis in dogs and cats, the availability of veterinary-labeled biologics, and a growing base of R&D investment dedicated to expanding the pipeline of species-specific monoclonal antibody therapies. Global animal health leaders are reallocating resources from conventional pharmaceuticals to biologics, fostering a wave of innovation supported by robust intellectual property frameworks and accelerated regulatory approvals in major veterinary markets. Simultaneously, the trend toward pet humanization and the surge in veterinary visits are amplifying demand for biologics that not only manage symptoms but also improve long-term clinical outcomes.
In addition to therapeutic advancements, the expansion of supportive infrastructure—such as cold-chain logistics, biologics-focused manufacturing facilities, and companion diagnostic platforms—is solidifying the commercial viability of veterinary mAbs. Collaborations between biotech startups, academic research institutes, and contract development and manufacturing organizations (CDMOs) are also driving down production costs and facilitating broader access to monoclonal antibody treatments. Furthermore, the increasing focus on non-invasive and personalized approaches to animal care is pushing boundaries in the veterinary biologics space, opening new therapeutic frontiers in both companion and large animal segments.
From a geographical standpoint, North America dominates the monoclonal antibodies in veterinary health market due to its advanced animal healthcare infrastructure, widespread pet insurance penetration, and strong regulatory support from bodies like the FDA and USDA. Europe follows closely, with favorable reimbursement policies and a proactive stance on innovation in pet therapeutics. However, the Asia Pacific region is forecasted to be the fastest-growing market during the projected period. Countries like China, Japan, and India are witnessing a boom in pet adoption, increasing disposable income, and strategic investments in animal biotechnology. Latin America and the Middle East & Africa, while still nascent, are showing promising signals through rising veterinary awareness and public-private partnerships in zoonotic disease control.
Major market player included in this report are:
• Zoetis Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Incorporated
• Virbac
• Merck Animal Health
• Aratana Therapeutics, Inc.
• Kindred Biosciences, Inc.
• Ligand Pharmaceuticals Inc.
• Nextmune
• PetMedix Ltd.
• Bayer Animal Health
• Zymeworks Inc.
• Kiniksa Pharmaceuticals
• Regeneron Pharmaceuticals
• Orion Corporation
The detailed segments and sub-segment of the market are explained below:
By Application
• Dermatology
• Pain
By Animal Type
• Companion Animals
• Livestock Animals
By End-user
• Veterinary Hospitals & Clinics
• Research & Academic Institutes
• Others
By Region:
North America
• U.S.
• Canada
Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
Latin America
• Brazil
• Mexico
Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA
Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032
Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1. Global Monoclonal Antibodies in Veterinary Health Market Executive Summary
1.1. Global Monoclonal Antibodies in Veterinary Health Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Application
1.3.2. By Animal Type
1.3.3. By End-user
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Monoclonal Antibodies in Veterinary Health Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Buyer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Stakeholder Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Monoclonal Antibodies in Veterinary Health Market Dynamics
3.1. Market Drivers
3.1.1. Rising Prevalence of Dermatological & Pain Conditions
3.1.2. Surging R&D Investment in Veterinary Biologics
3.1.3. Regulatory Support and Accelerated Approvals for mAbs
3.2. Market Challenges
3.2.1. High Development and Manufacturing Costs
3.2.2. Complex Cold-Chain Logistics Requirements
3.3. Market Opportunities
3.3.1. Expansion into Large Animal Therapeutics
3.3.2. Partnerships with CDMOs for Cost-Efficient Production
3.3.3. Integration of Companion Diagnostics and Personalized Care
Chapter 4. Global Monoclonal Antibodies in Veterinary Health Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Porter’s Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Monoclonal Antibodies in Veterinary Health Market Size & Forecasts by Application 2022–2032
5.1. Segment Dashboard
5.2. Global Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Dermatology
5.2.2. Pain
Chapter 6. Global Monoclonal Antibodies in Veterinary Health Market Size & Forecasts by Animal Type 2022–2032
6.1. Segment Dashboard
6.2. Global Market: Animal Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Companion Animals
6.2.2. Livestock Animals
Chapter 7. Global Monoclonal Antibodies in Veterinary Health Market Size & Forecasts by End-user 2022–2032
7.1. Segment Dashboard
7.2. Global Market: End-user Revenue Trend Analysis, 2022 & 2032 (USD Million)
7.2.1. Veterinary Hospitals & Clinics
7.2.2. Research & Academic Institutes
7.2.3. Others
Chapter 8. Global Monoclonal Antibodies in Veterinary Health Market Size & Forecasts by Region 2022–2032
8.1. North America
8.1.1. U.S. Market
8.1.1.1. Segment breakdown size & forecasts, 2022–2032
8.1.2. Canada Market
8.2. Europe
8.2.1. UK Market
8.2.2. Germany Market
8.2.3. France Market
8.2.4. Spain Market
8.2.5. Italy Market
8.2.6. Rest of Europe Market
8.3. Asia Pacific
8.3.1. China Market
8.3.2. India Market
8.3.3. Japan Market
8.3.4. Australia Market
8.3.5. South Korea Market
8.3.6. Rest of APAC Market
8.4. Latin America
8.4.1. Brazil Market
8.4.2. Mexico Market
8.5. Middle East & Africa
8.5.1. Saudi Arabia Market
8.5.2. South Africa Market
8.5.3. Rest of MEA Market
Chapter 9. Competitive Intelligence
9.1. Key Company SWOT Analysis
9.1.1. Zoetis Inc.
9.1.2. Boehringer Ingelheim International GmbH
9.1.3. Elanco Animal Health Incorporated
9.2. Top Market Strategies
9.3. Company Profiles
9.3.1. Zoetis Inc.
9.3.1.1. Key Information
9.3.1.2. Overview
9.3.1.3. Financial (Subject to Data Availability)
9.3.1.4. Product Summary
9.3.1.5. Market Strategies
9.3.2. Boehringer Ingelheim International GmbH
9.3.3. Elanco Animal Health Incorporated
9.3.4. Virbac
9.3.5. Merck Animal Health
9.3.6. Aratana Therapeutics, Inc.
9.3.7. Kindred Biosciences, Inc.
9.3.8. Ligand Pharmaceuticals Inc.
9.3.9. Nextmune
9.3.10. PetMedix Ltd.
9.3.11. Bayer Animal Health
9.3.12. Zymeworks Inc.
9.3.13. Kiniksa Pharmaceuticals
9.3.14. Regeneron Pharmaceuticals
9.3.15. Orion Corporation
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes